ArticleCurrent medicinal chemistry2025
Circulating Exosomal Transfer RNA-Related Fragments as Diagnostic Biomarkers for Non-small Cell Lung Cancer.
Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimExosomal transfer RNA-derived fragments (exo-tRF) possess the capacity to be employed as biomarkers for several types of cancer. We aim to ascertain the diagnostic significance of exosomal 5'tRF-TyrGTA and 5'tRF-ValTAC in non-small cell lung cancer (NSCLC).
methodsUltracentrifugation was deployed to obtain serum exosomes from NSCLC patients and healthy donors. The acquired exosomes were then confirmed by transmission electron microscopy (TEM), qNano, and Western blot (WB) techniques. The level of exo- tRF expression was validated by the use of microarrays and RT-qPCR. The diagnostic performance of exo-tRFs for NSCLC was determined through the receiver operating characteristic curve (ROC).
resultsExosomal 5'tRF-TyrGTA and 5'tRF-ValTAC were significantly downregulated in both early- and late-stage NSCLC patients compared to healthy donors, representing favorable diagnostic efficiency for NSCLC. In addition, the exosomal 5'tRF-TyrGTA level was correlated with tumor stage and lymph node metastasis.
conclusionExosomal 5'tRF-TyrGTA and 5'tRF-ValTAC can serve as potential biomarkers for NSCLC.
Indexed as
Identifiers
39161151What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.